CD30 +
About
Biomarker Type: Protein expression
Present: True
Marker: CD30
Unit: status
Equality: =
Value: Positive
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone | |
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Cutaneous T-cell Lymphoma | Brentuximab vedotin |